Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 337 citing articles:

EMT, cell plasticity and metastasis
Christine L. Chaffer, Beatriz P. San Juan, Elgene Lim, et al.
Cancer and Metastasis Reviews (2016) Vol. 35, Iss. 4, pp. 645-654
Closed Access | Times Cited: 766
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant P. Chawla, Robert G. Maki, et al.
The Lancet (2016) Vol. 387, Iss. 10028, pp. 1629-1637
Open Access | Times Cited: 706
Movers and shakers: cell cytoskeleton in cancer metastasis
Christopher M. Fife, Joshua A. McCarroll, Maria Kavallaris
British Journal of Pharmacology (2014) Vol. 171, Iss. 24, pp. 5507-5523
Open Access | Times Cited: 510
IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis
Landon Browning, Megha Patel, Eli Bring Horvath, et al.
Cancer Management and Research (2018) Vol. Volume 10, pp. 6685-6693
Open Access | Times Cited: 230
Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent
Nicholas F. Dybdal‐Hargreaves, April L. Risinger, Susan L. Mooberry
Clinical Cancer Research (2015) Vol. 21, Iss. 11, pp. 2445-2452
Open Access | Times Cited: 199
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves, Javier Cortés, Linda T. Vahdat, et al.
Breast Cancer Research and Treatment (2014) Vol. 148, Iss. 3, pp. 553-561
Open Access | Times Cited: 198
Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers
Kuo Chen, Jin Zhang, Narasimha M. Beeraka, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 77
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
George D. Demetri, Patrick Schöffski, Giovanni Grignani, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 30, pp. 3433-3439
Closed Access | Times Cited: 151
Molecular Classification of Triple-Negative Breast Cancer
Sung Gwe Ahn, Seung Jun Kim, Cheungyeul Kim, et al.
Journal of Breast Cancer (2016) Vol. 19, Iss. 3, pp. 223-223
Open Access | Times Cited: 134
Marine Sponge Natural Products with Anticancer Potential: An Updated Review
Cinzia Calcabrini, Elena Catanzaro, Anupam Bishayee, et al.
Marine Drugs (2017) Vol. 15, Iss. 10, pp. 310-310
Open Access | Times Cited: 134
The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas
Monica Fedele, Laura Cerchia, Gennaro Chiappetta
Cancers (2017) Vol. 9, Iss. 10, pp. 134-134
Open Access | Times Cited: 130
Epithelial-to-mesenchymal transition in tumor progression
Elena Prieto‐García, C. Vanesa Díaz-García, Inmaculada Garcı́a-Ruiz, et al.
Medical Oncology (2017) Vol. 34, Iss. 7
Closed Access | Times Cited: 127
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M. Tolaney, Romualdo Barroso‐Sousa, Tanya E. Keenan, et al.
JAMA Oncology (2020) Vol. 6, Iss. 10, pp. 1598-1598
Open Access | Times Cited: 120
Enriching cancer pharmacology with drugs of marine origin
Paula C. Jimenez, Diego Veras Wilke, Paola Cristina Branco, et al.
British Journal of Pharmacology (2019) Vol. 177, Iss. 1, pp. 3-27
Open Access | Times Cited: 115
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Maria Alice Franzoi, Emanuela Romano, Martine Piccart
Annals of Oncology (2020) Vol. 32, Iss. 3, pp. 323-336
Open Access | Times Cited: 103
Advances in sarcoma diagnostics and treatment
Amanda R. Dancsok, Karama Asleh, Torsten O. Nielsen
Oncotarget (2016) Vol. 8, Iss. 4, pp. 7068-7093
Open Access | Times Cited: 99
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
Shigeto Ueda, Toshiaki Saeki, Hideki Takeuchi, et al.
British Journal of Cancer (2016) Vol. 114, Iss. 11, pp. 1212-1218
Open Access | Times Cited: 98
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, et al.
PLoS ONE (2017) Vol. 12, Iss. 2, pp. e0170634-e0170634
Open Access | Times Cited: 93
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas
Alessandro De Vita, Laura Mercatali, Federica Recine, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 6233-6246
Open Access | Times Cited: 88
Microtubule-Targeting Drugs: More than Antimitotics
Roma Kaul, April L. Risinger, Susan L. Mooberry
Journal of Natural Products (2019) Vol. 82, Iss. 3, pp. 680-685
Closed Access | Times Cited: 84
Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets
Renato B. Pereira, Nikolai M. Evdokimov, Florence Lefranc, et al.
Marine Drugs (2019) Vol. 17, Iss. 6, pp. 329-329
Open Access | Times Cited: 82
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 14, pp. 3905-3915
Open Access | Times Cited: 77
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
Peng Yuan, Xichun Hu, Tao Sun, et al.
European Journal of Cancer (2019) Vol. 112, pp. 57-65
Open Access | Times Cited: 76
Therapies for triple negative breast cancer
Eleni Andreopoulou, Sarah J. Schweber, Joseph A. Sparano, et al.
Expert Opinion on Pharmacotherapy (2015) Vol. 16, Iss. 7, pp. 983-998
Open Access | Times Cited: 90
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
Gino K. In, James Hu, William W. Tseng
Therapeutic Advances in Medical Oncology (2017) Vol. 9, Iss. 8, pp. 533-550
Open Access | Times Cited: 86
Page 1 - Next Page

Scroll to top